Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Down 55.8% in June

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 137 shares, a decrease of 55.8% from the May 31st total of 310 shares. Based on an average daily volume of 3,304 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Enzon Pharmaceuticals Price Performance

Shares of OTCMKTS:ENZN opened at $5.11 on Monday. Enzon Pharmaceuticals has a one year low of $1.50 and a one year high of $12.99. The company has a 50 day moving average of $5.85 and a 200-day moving average of $5.70. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16. The stock has a market cap of $3.78 million, a price-to-earnings ratio of -0.75 and a beta of -0.06.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share for the quarter. The company had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.